| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 72 | 2024 | 589 | 7.910 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 58 | 2024 | 409 | 6.470 |
Why?
|
| Neoplasm Recurrence, Local | 42 | 2024 | 330 | 4.110 |
Why?
|
| Endometrial Neoplasms | 33 | 2024 | 189 | 3.280 |
Why?
|
| Peritoneal Neoplasms | 24 | 2018 | 79 | 2.960 |
Why?
|
| Paclitaxel | 34 | 2024 | 190 | 2.920 |
Why?
|
| Fallopian Tube Neoplasms | 15 | 2018 | 52 | 2.350 |
Why?
|
| Uterine Cervical Neoplasms | 27 | 2025 | 297 | 2.350 |
Why?
|
| Neoplasms, Glandular and Epithelial | 11 | 2019 | 72 | 2.320 |
Why?
|
| Carboplatin | 28 | 2024 | 111 | 2.100 |
Why?
|
| Middle Aged | 117 | 2025 | 7137 | 1.940 |
Why?
|
| Aged | 109 | 2025 | 5400 | 1.910 |
Why?
|
| Female | 161 | 2025 | 15153 | 1.820 |
Why?
|
| Aged, 80 and over | 69 | 2024 | 2021 | 1.750 |
Why?
|
| Bevacizumab | 17 | 2022 | 103 | 1.740 |
Why?
|
| Neoplasm Staging | 48 | 2022 | 478 | 1.600 |
Why?
|
| Disease-Free Survival | 40 | 2025 | 237 | 1.560 |
Why?
|
| Uterine Neoplasms | 15 | 2017 | 71 | 1.510 |
Why?
|
| Humans | 165 | 2025 | 28094 | 1.380 |
Why?
|
| Adult | 95 | 2025 | 7739 | 1.310 |
Why?
|
| Clinical Trials as Topic | 9 | 2021 | 214 | 1.270 |
Why?
|
| Genital Neoplasms, Female | 9 | 2021 | 67 | 1.250 |
Why?
|
| Lymph Node Excision | 18 | 2022 | 100 | 1.060 |
Why?
|
| Cisplatin | 26 | 2024 | 179 | 0.980 |
Why?
|
| Carcinoma, Squamous Cell | 11 | 2022 | 163 | 0.870 |
Why?
|
| Biomarkers, Tumor | 14 | 2021 | 404 | 0.850 |
Why?
|
| Protein Kinase Inhibitors | 8 | 2018 | 156 | 0.830 |
Why?
|
| Cytoreduction Surgical Procedures | 3 | 2019 | 33 | 0.820 |
Why?
|
| Carcinoma, Endometrioid | 8 | 2017 | 41 | 0.760 |
Why?
|
| Neoadjuvant Therapy | 5 | 2025 | 73 | 0.760 |
Why?
|
| Drug Administration Schedule | 21 | 2019 | 224 | 0.710 |
Why?
|
| Angiogenesis Inhibitors | 5 | 2017 | 109 | 0.700 |
Why?
|
| Lymph Nodes | 8 | 2022 | 103 | 0.680 |
Why?
|
| Prognosis | 21 | 2021 | 802 | 0.660 |
Why?
|
| Vulvar Neoplasms | 6 | 2022 | 25 | 0.660 |
Why?
|
| Chemoradiotherapy | 4 | 2025 | 44 | 0.650 |
Why?
|
| Quinazolines | 4 | 2015 | 32 | 0.630 |
Why?
|
| Patient Selection | 2 | 2014 | 148 | 0.630 |
Why?
|
| Antineoplastic Agents | 14 | 2024 | 679 | 0.620 |
Why?
|
| Hysterectomy | 11 | 2016 | 85 | 0.620 |
Why?
|
| Retrospective Studies | 26 | 2024 | 2546 | 0.600 |
Why?
|
| Randomized Controlled Trials as Topic | 10 | 2022 | 385 | 0.600 |
Why?
|
| Precision Medicine | 2 | 2016 | 76 | 0.580 |
Why?
|
| Medical Oncology | 6 | 2022 | 94 | 0.570 |
Why?
|
| Survival Analysis | 15 | 2021 | 288 | 0.570 |
Why?
|
| Laparoscopy | 8 | 2016 | 146 | 0.540 |
Why?
|
| Antineoplastic Agents, Phytogenic | 3 | 2018 | 55 | 0.540 |
Why?
|
| Chemotherapy, Adjuvant | 7 | 2011 | 113 | 0.530 |
Why?
|
| Carcinosarcoma | 4 | 2016 | 22 | 0.530 |
Why?
|
| Survival Rate | 15 | 2020 | 430 | 0.530 |
Why?
|
| Kaplan-Meier Estimate | 11 | 2019 | 194 | 0.520 |
Why?
|
| Gynecology | 3 | 2021 | 58 | 0.510 |
Why?
|
| Lymphatic Metastasis | 15 | 2022 | 125 | 0.500 |
Why?
|
| Prospective Studies | 17 | 2024 | 1248 | 0.470 |
Why?
|
| Pelvis | 8 | 2019 | 38 | 0.460 |
Why?
|
| Cystadenocarcinoma, Serous | 4 | 2017 | 32 | 0.460 |
Why?
|
| Antibodies, Monoclonal, Humanized | 8 | 2025 | 144 | 0.450 |
Why?
|
| Treatment Outcome | 22 | 2021 | 2377 | 0.430 |
Why?
|
| Quality of Life | 8 | 2021 | 487 | 0.420 |
Why?
|
| Infusions, Intravenous | 10 | 2019 | 102 | 0.410 |
Why?
|
| Proportional Hazards Models | 9 | 2019 | 226 | 0.410 |
Why?
|
| Sentinel Lymph Node | 2 | 2022 | 8 | 0.390 |
Why?
|
| Combined Modality Therapy | 14 | 2019 | 300 | 0.370 |
Why?
|
| Leiomyosarcoma | 4 | 2015 | 10 | 0.350 |
Why?
|
| Carcinoma | 4 | 2017 | 74 | 0.350 |
Why?
|
| Adenocarcinoma | 14 | 2017 | 298 | 0.340 |
Why?
|
| Ascites | 3 | 2002 | 19 | 0.330 |
Why?
|
| Mifepristone | 1 | 2009 | 4 | 0.330 |
Why?
|
| Reoperation | 4 | 2019 | 145 | 0.320 |
Why?
|
| Positron Emission Tomography Computed Tomography | 3 | 2020 | 31 | 0.320 |
Why?
|
| Pyrimidines | 2 | 2024 | 125 | 0.300 |
Why?
|
| United States | 9 | 2022 | 2146 | 0.290 |
Why?
|
| Leiomyoma | 1 | 2008 | 9 | 0.290 |
Why?
|
| Young Adult | 11 | 2019 | 2732 | 0.290 |
Why?
|
| Neoplasms | 3 | 2022 | 808 | 0.280 |
Why?
|
| Adenocarcinoma, Clear Cell | 3 | 2017 | 20 | 0.280 |
Why?
|
| Neonatal Nursing | 1 | 2006 | 3 | 0.270 |
Why?
|
| Hospitals, Teaching | 1 | 2006 | 26 | 0.270 |
Why?
|
| Postnatal Care | 1 | 2006 | 18 | 0.260 |
Why?
|
| Nursing Staff, Hospital | 1 | 2006 | 19 | 0.260 |
Why?
|
| Time Factors | 8 | 2021 | 1591 | 0.260 |
Why?
|
| Cohort Studies | 9 | 2017 | 887 | 0.260 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2017 | 167 | 0.260 |
Why?
|
| Breast Feeding | 1 | 2006 | 94 | 0.250 |
Why?
|
| Double-Blind Method | 8 | 2021 | 417 | 0.240 |
Why?
|
| Radiotherapy, Adjuvant | 4 | 2019 | 60 | 0.240 |
Why?
|
| Benzimidazoles | 2 | 2017 | 32 | 0.230 |
Why?
|
| Job Satisfaction | 1 | 2005 | 24 | 0.230 |
Why?
|
| Fellowships and Scholarships | 1 | 2005 | 39 | 0.230 |
Why?
|
| Salvage Therapy | 1 | 2004 | 34 | 0.230 |
Why?
|
| Indoles | 3 | 2022 | 99 | 0.230 |
Why?
|
| Nitriles | 1 | 2024 | 33 | 0.220 |
Why?
|
| Mutation | 3 | 2017 | 845 | 0.220 |
Why?
|
| Gestational Trophoblastic Disease | 2 | 2016 | 6 | 0.220 |
Why?
|
| Administration, Oral | 6 | 2018 | 189 | 0.220 |
Why?
|
| Pyrazoles | 1 | 2024 | 66 | 0.220 |
Why?
|
| Folic Acid Antagonists | 2 | 2009 | 17 | 0.210 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2021 | 474 | 0.210 |
Why?
|
| ErbB Receptors | 7 | 2013 | 100 | 0.210 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2017 | 607 | 0.210 |
Why?
|
| Physician's Role | 1 | 2003 | 29 | 0.210 |
Why?
|
| Infusions, Parenteral | 3 | 2019 | 37 | 0.200 |
Why?
|
| Lymphadenopathy | 1 | 2022 | 2 | 0.200 |
Why?
|
| Brachytherapy | 3 | 2024 | 51 | 0.200 |
Why?
|
| CA-125 Antigen | 4 | 2022 | 19 | 0.190 |
Why?
|
| Laparotomy | 5 | 2016 | 29 | 0.190 |
Why?
|
| Guanine | 2 | 2014 | 25 | 0.190 |
Why?
|
| Glutamates | 2 | 2014 | 14 | 0.190 |
Why?
|
| Gynecologic Surgical Procedures | 4 | 2011 | 35 | 0.190 |
Why?
|
| Cancer Survivors | 1 | 2022 | 43 | 0.190 |
Why?
|
| Radiation Dosage | 1 | 2021 | 54 | 0.180 |
Why?
|
| Subcutaneous Fat | 1 | 2021 | 17 | 0.180 |
Why?
|
| Drug Industry | 1 | 2021 | 14 | 0.180 |
Why?
|
| Intra-Abdominal Fat | 1 | 2021 | 21 | 0.180 |
Why?
|
| Diagnostic Imaging | 2 | 2022 | 68 | 0.180 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2017 | 27 | 0.180 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2017 | 21 | 0.180 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 42 | 0.170 |
Why?
|
| Doxorubicin | 7 | 2017 | 77 | 0.170 |
Why?
|
| Taxoids | 5 | 2015 | 37 | 0.170 |
Why?
|
| Radiopharmaceuticals | 2 | 2017 | 71 | 0.170 |
Why?
|
| Radiotherapy | 3 | 2009 | 41 | 0.170 |
Why?
|
| Catheterization, Central Venous | 2 | 2003 | 38 | 0.170 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 2 | 2017 | 13 | 0.170 |
Why?
|
| Practice Guidelines as Topic | 2 | 2019 | 243 | 0.160 |
Why?
|
| Stilbenes | 1 | 2020 | 90 | 0.160 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2022 | 251 | 0.160 |
Why?
|
| Vagina | 2 | 2019 | 42 | 0.160 |
Why?
|
| Health Planning Councils | 1 | 2019 | 2 | 0.160 |
Why?
|
| Anilides | 1 | 2018 | 19 | 0.150 |
Why?
|
| DNA Mutational Analysis | 2 | 2016 | 94 | 0.150 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2014 | 29 | 0.150 |
Why?
|
| Interleukin-6 | 1 | 2020 | 193 | 0.150 |
Why?
|
| Brain Neoplasms | 1 | 2001 | 301 | 0.150 |
Why?
|
| Pelvic Neoplasms | 2 | 1995 | 8 | 0.150 |
Why?
|
| Neoplasm, Residual | 1 | 2018 | 31 | 0.150 |
Why?
|
| Disease Progression | 2 | 2019 | 473 | 0.150 |
Why?
|
| Follow-Up Studies | 7 | 2020 | 1013 | 0.150 |
Why?
|
| Neoplasm Invasiveness | 6 | 2016 | 190 | 0.140 |
Why?
|
| Recombinational DNA Repair | 1 | 2017 | 7 | 0.140 |
Why?
|
| Pyridines | 1 | 2018 | 107 | 0.140 |
Why?
|
| Receptor, Notch2 | 1 | 2017 | 1 | 0.140 |
Why?
|
| DNA Copy Number Variations | 1 | 2017 | 36 | 0.140 |
Why?
|
| Biomedical Research | 1 | 2019 | 97 | 0.140 |
Why?
|
| Risk Factors | 8 | 2016 | 2081 | 0.140 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 89 | 0.140 |
Why?
|
| Cervix Uteri | 2 | 2022 | 65 | 0.140 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2018 | 107 | 0.140 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 1 | 2017 | 23 | 0.140 |
Why?
|
| Aminopterin | 1 | 1997 | 1 | 0.140 |
Why?
|
| Calcium-Binding Proteins | 1 | 2017 | 62 | 0.140 |
Why?
|
| gamma-Synuclein | 1 | 2016 | 2 | 0.140 |
Why?
|
| Pemetrexed | 2 | 2014 | 7 | 0.130 |
Why?
|
| Cyanoacrylates | 1 | 2016 | 2 | 0.130 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2017 | 9 | 0.130 |
Why?
|
| Curettage | 1 | 2016 | 4 | 0.130 |
Why?
|
| Glycolysis | 1 | 2017 | 85 | 0.130 |
Why?
|
| Predictive Value of Tests | 5 | 2024 | 474 | 0.130 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2016 | 15 | 0.130 |
Why?
|
| Cation Transport Proteins | 1 | 2017 | 60 | 0.130 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 1996 | 4 | 0.130 |
Why?
|
| Triazines | 2 | 2014 | 11 | 0.130 |
Why?
|
| Portasystemic Shunt, Surgical | 1 | 1996 | 4 | 0.130 |
Why?
|
| Obesity | 1 | 2002 | 669 | 0.130 |
Why?
|
| Germ-Line Mutation | 1 | 2016 | 30 | 0.130 |
Why?
|
| Proctocolectomy, Restorative | 1 | 1995 | 2 | 0.130 |
Why?
|
| Urinary Reservoirs, Continent | 1 | 1995 | 13 | 0.130 |
Why?
|
| Surgical Wound Infection | 1 | 2016 | 105 | 0.120 |
Why?
|
| Deoxycytidine | 4 | 2015 | 65 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor A | 5 | 2017 | 179 | 0.120 |
Why?
|
| Medroxyprogesterone Acetate | 2 | 2014 | 21 | 0.120 |
Why?
|
| Adolescent | 4 | 2016 | 3121 | 0.120 |
Why?
|
| Immunohistochemistry | 7 | 2016 | 463 | 0.120 |
Why?
|
| National Cancer Institute (U.S.) | 3 | 2022 | 29 | 0.120 |
Why?
|
| Epothilones | 1 | 2014 | 5 | 0.120 |
Why?
|
| Tubulin Modulators | 1 | 2014 | 17 | 0.110 |
Why?
|
| Feasibility Studies | 5 | 2011 | 193 | 0.110 |
Why?
|
| Alanine | 1 | 2014 | 40 | 0.110 |
Why?
|
| Organoplatinum Compounds | 3 | 2010 | 24 | 0.110 |
Why?
|
| Sensitivity and Specificity | 3 | 2017 | 521 | 0.110 |
Why?
|
| Cognition Disorders | 1 | 2015 | 184 | 0.110 |
Why?
|
| MicroRNAs | 1 | 2017 | 301 | 0.110 |
Why?
|
| Carcinoma, Adenosquamous | 3 | 2017 | 12 | 0.100 |
Why?
|
| Neoplasm Grading | 3 | 2018 | 104 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2012 | 26 | 0.100 |
Why?
|
| Iliac Aneurysm | 1 | 1992 | 8 | 0.100 |
Why?
|
| Maximum Tolerated Dose | 4 | 2017 | 31 | 0.100 |
Why?
|
| Abdomen | 3 | 2005 | 41 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 666 | 0.100 |
Why?
|
| Tamoxifen | 2 | 2010 | 33 | 0.100 |
Why?
|
| Niacinamide | 1 | 2013 | 31 | 0.100 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2013 | 97 | 0.100 |
Why?
|
| Treatment Failure | 4 | 2009 | 69 | 0.100 |
Why?
|
| Cognition | 1 | 2015 | 324 | 0.100 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2012 | 5 | 0.100 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2012 | 6 | 0.100 |
Why?
|
| Thiazoles | 1 | 2012 | 51 | 0.100 |
Why?
|
| Ovariectomy | 1 | 2012 | 53 | 0.090 |
Why?
|
| Diagnosis, Differential | 3 | 2008 | 371 | 0.090 |
Why?
|
| Risk Assessment | 4 | 2017 | 612 | 0.090 |
Why?
|
| Ifosfamide | 3 | 2007 | 9 | 0.090 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2011 | 25 | 0.090 |
Why?
|
| Dactinomycin | 1 | 2011 | 5 | 0.090 |
Why?
|
| Protein Kinase C | 1 | 2011 | 73 | 0.090 |
Why?
|
| Methotrexate | 1 | 2011 | 35 | 0.090 |
Why?
|
| Sirolimus | 1 | 2011 | 76 | 0.090 |
Why?
|
| Thalidomide | 1 | 2010 | 13 | 0.090 |
Why?
|
| Academic Medical Centers | 1 | 2010 | 75 | 0.090 |
Why?
|
| Urinary Diversion | 1 | 1990 | 26 | 0.080 |
Why?
|
| Preoperative Care | 3 | 2018 | 81 | 0.080 |
Why?
|
| Boronic Acids | 1 | 2009 | 9 | 0.080 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2009 | 10 | 0.080 |
Why?
|
| Pyrazines | 1 | 2009 | 24 | 0.080 |
Why?
|
| Karnofsky Performance Status | 1 | 2009 | 15 | 0.080 |
Why?
|
| Cooperative Behavior | 2 | 2020 | 77 | 0.080 |
Why?
|
| Platinum Compounds | 1 | 2009 | 14 | 0.080 |
Why?
|
| Sodium Chloride | 1 | 1989 | 65 | 0.080 |
Why?
|
| Creatinine | 1 | 2009 | 59 | 0.080 |
Why?
|
| Cyclophosphamide | 2 | 2008 | 41 | 0.080 |
Why?
|
| Recurrence | 4 | 2012 | 322 | 0.080 |
Why?
|
| Sarcoma, Experimental | 1 | 1988 | 2 | 0.080 |
Why?
|
| Weight Loss | 1 | 2009 | 81 | 0.070 |
Why?
|
| Meigs Syndrome | 1 | 2008 | 1 | 0.070 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2008 | 1 | 0.070 |
Why?
|
| Gene Expression | 3 | 2016 | 417 | 0.070 |
Why?
|
| Endpoint Determination | 3 | 2013 | 18 | 0.070 |
Why?
|
| Mesna | 1 | 2007 | 5 | 0.070 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2005 | 48 | 0.070 |
Why?
|
| Protective Agents | 1 | 2007 | 17 | 0.070 |
Why?
|
| Comorbidity | 1 | 2008 | 258 | 0.070 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2008 | 163 | 0.070 |
Why?
|
| Surveys and Questionnaires | 2 | 2015 | 971 | 0.070 |
Why?
|
| Consultants | 1 | 2006 | 4 | 0.070 |
Why?
|
| Filgrastim | 2 | 2020 | 7 | 0.070 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2006 | 58 | 0.060 |
Why?
|
| Conization | 1 | 2006 | 11 | 0.060 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2006 | 42 | 0.060 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2006 | 35 | 0.060 |
Why?
|
| Societies, Medical | 2 | 2017 | 93 | 0.060 |
Why?
|
| Cervical Intraepithelial Neoplasia | 1 | 2006 | 82 | 0.060 |
Why?
|
| Length of Stay | 2 | 2009 | 229 | 0.060 |
Why?
|
| DNA, Neoplasm | 2 | 2017 | 34 | 0.060 |
Why?
|
| Age Factors | 2 | 2018 | 734 | 0.060 |
Why?
|
| Neoplasm Metastasis | 2 | 2016 | 162 | 0.060 |
Why?
|
| Mentors | 1 | 2005 | 39 | 0.060 |
Why?
|
| B7-H1 Antigen | 1 | 2025 | 38 | 0.060 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2025 | 77 | 0.060 |
Why?
|
| Confidence Intervals | 2 | 2017 | 68 | 0.060 |
Why?
|
| Career Choice | 1 | 2005 | 53 | 0.060 |
Why?
|
| Education, Medical, Graduate | 1 | 2005 | 108 | 0.060 |
Why?
|
| HIV Infections | 1 | 2006 | 159 | 0.050 |
Why?
|
| Catheters, Indwelling | 1 | 2003 | 19 | 0.050 |
Why?
|
| Ultrasonography | 2 | 2016 | 241 | 0.050 |
Why?
|
| Ambulatory Care | 1 | 2003 | 60 | 0.050 |
Why?
|
| Etoposide | 1 | 2003 | 19 | 0.050 |
Why?
|
| Infant, Newborn | 1 | 2006 | 885 | 0.050 |
Why?
|
| Injections, Intravenous | 3 | 2011 | 65 | 0.050 |
Why?
|
| Polyethylene Glycols | 2 | 2017 | 101 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2003 | 25 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2003 | 47 | 0.050 |
Why?
|
| Infant | 1 | 2006 | 1004 | 0.050 |
Why?
|
| Groin | 1 | 2022 | 3 | 0.050 |
Why?
|
| Ovary | 2 | 2020 | 69 | 0.050 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2022 | 17 | 0.050 |
Why?
|
| Area Under Curve | 2 | 2018 | 95 | 0.050 |
Why?
|
| Research Design | 2 | 2014 | 184 | 0.050 |
Why?
|
| Ki-67 Antigen | 2 | 2013 | 23 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 1 | 2022 | 112 | 0.050 |
Why?
|
| Supervised Machine Learning | 1 | 2022 | 8 | 0.050 |
Why?
|
| Endometrium | 1 | 2022 | 39 | 0.050 |
Why?
|
| Aorta, Abdominal | 1 | 2002 | 15 | 0.050 |
Why?
|
| Hysterectomy, Vaginal | 1 | 2001 | 4 | 0.050 |
Why?
|
| Lymphocele | 1 | 2001 | 2 | 0.050 |
Why?
|
| Inguinal Canal | 1 | 2001 | 3 | 0.050 |
Why?
|
| Neoplasm Micrometastasis | 1 | 2021 | 6 | 0.050 |
Why?
|
| Meta-Analysis as Topic | 1 | 2001 | 32 | 0.050 |
Why?
|
| Cellulitis | 1 | 2001 | 7 | 0.050 |
Why?
|
| Lymphedema | 1 | 2001 | 15 | 0.050 |
Why?
|
| Survivors | 1 | 2021 | 40 | 0.050 |
Why?
|
| Aorta, Thoracic | 1 | 2001 | 55 | 0.040 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2001 | 37 | 0.040 |
Why?
|
| Pentoxifylline | 1 | 2000 | 2 | 0.040 |
Why?
|
| Injections, Intraperitoneal | 2 | 2012 | 35 | 0.040 |
Why?
|
| Topotecan | 1 | 2000 | 12 | 0.040 |
Why?
|
| Biopsy, Needle | 2 | 2011 | 48 | 0.040 |
Why?
|
| Aorta | 1 | 2001 | 124 | 0.040 |
Why?
|
| Cetuximab | 2 | 2012 | 21 | 0.040 |
Why?
|
| Health Services Research | 1 | 2020 | 43 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2017 | 465 | 0.040 |
Why?
|
| Adiposity | 1 | 2021 | 94 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2011 | 155 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2020 | 110 | 0.040 |
Why?
|
| Pregnancy | 2 | 2016 | 1191 | 0.040 |
Why?
|
| Subrenal Capsule Assay | 2 | 1989 | 5 | 0.040 |
Why?
|
| Receptors, Progesterone | 2 | 2013 | 17 | 0.040 |
Why?
|
| Anemia | 2 | 2015 | 43 | 0.040 |
Why?
|
| Costs and Cost Analysis | 2 | 1999 | 40 | 0.040 |
Why?
|
| Algorithms | 1 | 2022 | 430 | 0.040 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2010 | 18 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 2 | 2012 | 329 | 0.040 |
Why?
|
| Apoptosis | 2 | 2017 | 775 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2018 | 125 | 0.040 |
Why?
|
| Laparoscopes | 1 | 1998 | 3 | 0.040 |
Why?
|
| Thrombocytopenia | 2 | 2015 | 113 | 0.040 |
Why?
|
| Neuropilin-1 | 1 | 2017 | 5 | 0.040 |
Why?
|
| Postoperative Care | 1 | 2018 | 68 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2017 | 13 | 0.040 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2017 | 13 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2017 | 12 | 0.040 |
Why?
|
| Endodermal Sinus Tumor | 1 | 1997 | 3 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2017 | 56 | 0.030 |
Why?
|
| Pyruvate Dehydrogenase Complex | 1 | 2017 | 19 | 0.030 |
Why?
|
| Oxidative Phosphorylation | 1 | 2017 | 29 | 0.030 |
Why?
|
| Benzazepines | 1 | 2017 | 12 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2002 | 819 | 0.030 |
Why?
|
| Fanconi Syndrome | 1 | 1997 | 1 | 0.030 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2017 | 8 | 0.030 |
Why?
|
| Exons | 1 | 2017 | 42 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2017 | 64 | 0.030 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2017 | 22 | 0.030 |
Why?
|
| Microvessels | 1 | 2017 | 87 | 0.030 |
Why?
|
| Chlorhexidine | 1 | 2016 | 7 | 0.030 |
Why?
|
| ROC Curve | 1 | 2017 | 144 | 0.030 |
Why?
|
| Adjuvants, Immunologic | 1 | 2017 | 68 | 0.030 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2016 | 10 | 0.030 |
Why?
|
| Chorionic Gonadotropin | 1 | 2016 | 22 | 0.030 |
Why?
|
| Jugular Veins | 1 | 1996 | 13 | 0.030 |
Why?
|
| Animals | 5 | 2017 | 10415 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2017 | 331 | 0.030 |
Why?
|
| Postoperative Complications | 2 | 2003 | 611 | 0.030 |
Why?
|
| Contrast Media | 1 | 2017 | 96 | 0.030 |
Why?
|
| Calcium | 1 | 2017 | 235 | 0.030 |
Why?
|
| Ileocecal Valve | 1 | 1995 | 2 | 0.030 |
Why?
|
| Urinary Catheterization | 1 | 1995 | 15 | 0.030 |
Why?
|
| Stents | 1 | 1996 | 120 | 0.030 |
Why?
|
| Fluorouracil | 3 | 2005 | 58 | 0.030 |
Why?
|
| Reaction Time | 1 | 2015 | 94 | 0.030 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2015 | 12 | 0.030 |
Why?
|
| Genomics | 1 | 2016 | 123 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2015 | 67 | 0.030 |
Why?
|
| Patients' Rooms | 1 | 1994 | 2 | 0.030 |
Why?
|
| Incidence | 2 | 2007 | 562 | 0.030 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2015 | 37 | 0.030 |
Why?
|
| Attention | 1 | 2015 | 90 | 0.030 |
Why?
|
| Phenotype | 1 | 2017 | 680 | 0.030 |
Why?
|
| Operating Rooms | 1 | 1994 | 19 | 0.030 |
Why?
|
| Immunity, Innate | 1 | 2017 | 226 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2011 | 302 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2016 | 433 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 769 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 414 | 0.030 |
Why?
|
| Drug Approval | 1 | 2013 | 10 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 1989 | 1574 | 0.030 |
Why?
|
| Radiotherapy Dosage | 2 | 2005 | 104 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 961 | 0.030 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor | 1 | 2013 | 3 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2017 | 1319 | 0.030 |
Why?
|
| Oligonucleotides | 1 | 2013 | 27 | 0.030 |
Why?
|
| Placebos | 1 | 2012 | 48 | 0.030 |
Why?
|
| Maintenance Chemotherapy | 1 | 2012 | 17 | 0.030 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2012 | 31 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2013 | 43 | 0.030 |
Why?
|
| ras Proteins | 1 | 2012 | 43 | 0.030 |
Why?
|
| Dasatinib | 1 | 2012 | 18 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2012 | 63 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2012 | 95 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 523 | 0.020 |
Why?
|
| Myelitis | 1 | 1991 | 3 | 0.020 |
Why?
|
| DNA Mismatch Repair | 1 | 2012 | 12 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2012 | 140 | 0.020 |
Why?
|
| Pedigree | 1 | 2012 | 155 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2011 | 50 | 0.020 |
Why?
|
| Protein Kinase C beta | 1 | 2011 | 4 | 0.020 |
Why?
|
| Cyclin D1 | 1 | 2011 | 38 | 0.020 |
Why?
|
| Genes, p53 | 1 | 2011 | 14 | 0.020 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2011 | 15 | 0.020 |
Why?
|
| Catheterization | 1 | 2011 | 50 | 0.020 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2011 | 29 | 0.020 |
Why?
|
| Pulse Therapy, Drug | 1 | 2011 | 2 | 0.020 |
Why?
|
| Ontario | 1 | 2011 | 10 | 0.020 |
Why?
|
| Choriocarcinoma | 1 | 2011 | 6 | 0.020 |
Why?
|
| Injections, Intramuscular | 1 | 2011 | 22 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2011 | 165 | 0.020 |
Why?
|
| Consensus | 1 | 2011 | 75 | 0.020 |
Why?
|
| Mice | 3 | 1989 | 4650 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2011 | 82 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2011 | 128 | 0.020 |
Why?
|
| International Cooperation | 1 | 2010 | 20 | 0.020 |
Why?
|
| Fibroma | 1 | 1990 | 6 | 0.020 |
Why?
|
| Bridged-Ring Compounds | 1 | 2010 | 18 | 0.020 |
Why?
|
| Self Medication | 1 | 1990 | 4 | 0.020 |
Why?
|
| Morphine | 1 | 1990 | 29 | 0.020 |
Why?
|
| Pelvic Exenteration | 1 | 1990 | 2 | 0.020 |
Why?
|
| Vesicovaginal Fistula | 1 | 1990 | 4 | 0.020 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2010 | 18 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2011 | 135 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2011 | 236 | 0.020 |
Why?
|
| Hematologic Diseases | 1 | 2010 | 11 | 0.020 |
Why?
|
| Cecum | 1 | 1990 | 14 | 0.020 |
Why?
|
| Ileum | 1 | 1990 | 25 | 0.020 |
Why?
|
| Probability | 1 | 2010 | 78 | 0.020 |
Why?
|
| Endometriosis | 1 | 1990 | 19 | 0.020 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1990 | 26 | 0.020 |
Why?
|
| Radiation Injuries | 1 | 1990 | 52 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2011 | 135 | 0.020 |
Why?
|
| Pain, Postoperative | 1 | 1990 | 62 | 0.020 |
Why?
|
| Logistic Models | 1 | 2011 | 407 | 0.020 |
Why?
|
| Fever | 1 | 2009 | 31 | 0.020 |
Why?
|
| Bortezomib | 1 | 2009 | 22 | 0.020 |
Why?
|
| Pharmaceutical Vehicles | 1 | 1989 | 7 | 0.020 |
Why?
|
| Abscess | 1 | 2009 | 24 | 0.020 |
Why?
|
| Protease Inhibitors | 1 | 2009 | 40 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2010 | 167 | 0.020 |
Why?
|
| Intraoperative Complications | 1 | 2009 | 47 | 0.020 |
Why?
|
| Urinary Tract Infections | 1 | 2009 | 39 | 0.020 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2009 | 80 | 0.020 |
Why?
|
| Male | 1 | 2005 | 13489 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2010 | 413 | 0.020 |
Why?
|
| Analgesics, Opioid | 1 | 1990 | 113 | 0.020 |
Why?
|
| Polyglutamic Acid | 1 | 2008 | 3 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 1988 | 90 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2008 | 79 | 0.020 |
Why?
|
| Actuarial Analysis | 3 | 1992 | 6 | 0.020 |
Why?
|
| Kidney | 1 | 1989 | 286 | 0.020 |
Why?
|
| Vincristine | 1 | 2007 | 9 | 0.020 |
Why?
|
| Abdominal Cavity | 1 | 2006 | 1 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2006 | 25 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2007 | 67 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2013 | 1435 | 0.020 |
Why?
|
| Electrosurgery | 1 | 2006 | 15 | 0.020 |
Why?
|
| Second-Look Surgery | 1 | 2005 | 4 | 0.020 |
Why?
|
| Cause of Death | 1 | 2005 | 73 | 0.020 |
Why?
|
| HIV-1 | 1 | 2006 | 58 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2006 | 75 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2005 | 104 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2006 | 257 | 0.020 |
Why?
|
| Capecitabine | 1 | 2005 | 3 | 0.010 |
Why?
|
| Thymidine Phosphorylase | 1 | 2005 | 2 | 0.010 |
Why?
|
| Thymidylate Synthase | 1 | 2005 | 7 | 0.010 |
Why?
|
| Dihydrouracil Dehydrogenase (NADP) | 1 | 2005 | 9 | 0.010 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2005 | 103 | 0.010 |
Why?
|
| Lymphatic System | 1 | 2004 | 11 | 0.010 |
Why?
|
| Megestrol Acetate | 1 | 2004 | 5 | 0.010 |
Why?
|
| Subclavian Vein | 1 | 2003 | 4 | 0.010 |
Why?
|
| Equipment Failure | 1 | 2003 | 31 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2003 | 82 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2004 | 199 | 0.010 |
Why?
|
| Radiography | 1 | 2003 | 202 | 0.010 |
Why?
|
| Bleomycin | 1 | 2002 | 11 | 0.010 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2002 | 21 | 0.010 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2002 | 32 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2004 | 407 | 0.010 |
Why?
|
| Leukopenia | 1 | 2000 | 5 | 0.010 |
Why?
|
| Remission Induction | 1 | 2000 | 53 | 0.010 |
Why?
|
| Neutropenia | 1 | 2000 | 41 | 0.010 |
Why?
|
| Oklahoma | 1 | 2003 | 1007 | 0.010 |
Why?
|
| Ultrasonics | 1 | 1998 | 7 | 0.010 |
Why?
|
| Hemostasis, Surgical | 1 | 1998 | 7 | 0.010 |
Why?
|
| Surgical Instruments | 1 | 1998 | 15 | 0.010 |
Why?
|
| Drug Therapy | 1 | 1997 | 15 | 0.010 |
Why?
|
| Drug Resistance, Multiple | 1 | 1997 | 20 | 0.010 |
Why?
|
| Epithelium | 1 | 1997 | 39 | 0.010 |
Why?
|
| Tissue Fixation | 1 | 1994 | 7 | 0.010 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 1994 | 5 | 0.010 |
Why?
|
| Formaldehyde | 1 | 1994 | 11 | 0.010 |
Why?
|
| Paraffin Embedding | 1 | 1994 | 14 | 0.010 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 1994 | 19 | 0.010 |
Why?
|
| Oncogene Proteins, Viral | 1 | 1994 | 16 | 0.010 |
Why?
|
| Receptor, ErbB-2 | 1 | 1994 | 33 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 1994 | 103 | 0.010 |
Why?
|
| Uterus | 1 | 1992 | 31 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 1994 | 247 | 0.010 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 1990 | 12 | 0.010 |
Why?
|
| Infusion Pumps | 1 | 1990 | 3 | 0.010 |
Why?
|
| Pain Measurement | 1 | 1990 | 166 | 0.010 |
Why?
|
| Medroxyprogesterone | 1 | 1989 | 4 | 0.000 |
Why?
|
| Evaluation Studies as Topic | 1 | 1989 | 43 | 0.000 |
Why?
|
| Carcinoma, Papillary | 1 | 1989 | 18 | 0.000 |
Why?
|
| Carcinoma, Small Cell | 1 | 1989 | 15 | 0.000 |
Why?
|